Research Peptides vs SARMs: Chemistry, Targets, Assay Design and Documentation

The question "peptides or SARMs" compares two things that are not the same kind of category. "Peptide" names a chemical class: a polymer of alpha-amino acids joined by amide bonds. "SARM" names a pharmacological class: a ligand of one specific nuclear receptor, defined by its target and by a selectivity hypothesis rather than by its chemistry. A compound can belong to neither, and this catalogue stocks several that do — ibutamoren is a non-peptide spiropiperidine, SR9011 is a nuclear-receptor agonist that is not an androgen ligand, bromantane is an adamantane derivative. The useful comparison is not which class is better but what each class forces you to change in an experiment.

What follows compares the two on the things that determine a protocol: structure and molecular size, target class and therefore assay design, solubility and vehicle, degradation chemistry, which analytical methods can actually prove identity, and documented regulatory status. All of it describes research chemicals for in-vitro and preclinical laboratory work only.

Structure and size

The peptides in this catalogue run from KPV at 342.43 g/mol to tesamorelin at 5,135.86, with the bulk of the working range between 700 and 1,500. They are built on a repeating amide backbone, constructed from chiral L-residues with occasional D-substitutions or unnatural residues inserted deliberately, and they are polar and usually charged at neutral pH, which is why they dissolve in bacteriostatic or sterile water and need no organic solvent.

The androgen-receptor ligands occupy a narrow band an order of magnitude lower: ACP-105 at 290.79 g/mol, LGD-4033 at 338.25, MK-2866 at 389.33, RAD-140 at 393.83, S-23 at 416.76, YK-11 at 430.54 and S-4 at 441.36. They are single small organic molecules, not polymers. The scaffolds are mostly aryl propionamides — the series that includes andarine and S-23 — or substituted benzonitriles, and heavily fluorinated: LGD-4033 is C14H12F6N2O, S-4 is C19H18F3N3O6, S-23 is C18H13ClF4N2O3. Fluorine substitution is there to block oxidative metabolism, which is the small-molecule equivalent of inserting a D-amino acid to block a peptidase.

One member of the class contradicts the class name, and it is worth knowing which. YK-11 is steroidal: a 5-alpha-androstane nucleus bearing a gem-dimethyl malonate ester at C-17. It is catalogued as a partial androgen-receptor agonist, and it behaves as a selective modulator in assay work, but "non-steroidal" is a statement about most SARMs rather than all of them. The definitional question is covered in the SARM glossary entry.

Target class is what changes the assay

This is the difference that reaches furthest into experimental design. Most of the peptides here act at cell-surface receptors — GHS-R1a for the GHRPs, the GHRH receptor for sermorelin and the CJC-1295 analogues, GLP-1 and GIP receptors for the incretins, melanocortin receptors for PT-141 and Melanotan I — or at extracellular and matrix targets, as the copper tripeptides and the thymosin fragments do. Androgen-receptor ligands act at NR3C4, a ligand-activated transcription factor that sits in the cytoplasm until it binds, then translocates to the nucleus and recruits coregulators to androgen response elements.

Those two mechanisms are measured with different experiments on different clocks. Surface-receptor pharmacology is read as second-messenger output — cAMP accumulation, calcium flux, beta-arrestin recruitment — within seconds to minutes of ligand addition, with potency expressed as an EC50 from a concentration–response curve. Nuclear-receptor pharmacology needs competitive binding against a labelled reference ligand to establish affinity, then a transactivation reporter assay to establish whether binding produces transcription, then transcript or protein endpoints over hours to days. A design built for one reads nothing useful from the other, and the catalogue's AR ligands all list "AR binding and transactivation assays" among their research areas for that reason.

Tissue selectivity, the property the acronym asserts, is a hypothesis rather than a measurement. It is attributed to ligand-specific receptor conformations recruiting different coregulator sets in different tissues, reinforced by the fact that non-steroidal ligands are not substrates for 5-alpha-reductase or aromatase. The supporting evidence is largely rodent and cell work plus early-phase human trials; no compound in this class has completed a successful phase 3 programme. Any study that treats selectivity as given has assumed its conclusion.

Solubility, vehicle and the controls that follow

Research peptides dissolve in water. Bacteriostatic water or sterile water is the whole vehicle question for most of them, with the exceptions being the deliberately lipophilic ones — Dihexa is poorly water-soluble because it carries hexanoyl and aminohexanoyl groups at its termini, and P-21 carries an adamantyl group — both of which need a co-solvent step before dilution.

Androgen-receptor ligands are poorly water-soluble as a class. Powder stocks are prepared in DMSO or ethanol, and the catalogue's research liquids use a solvent carrier at 20 mg/mL in a 30 mL dropper bottle. That has three consequences a peptide protocol never has to handle. A vehicle-only control becomes mandatory, because DMSO is not inert in cell culture. The top concentration is capped by the solvent rather than by the compound, since most cell assays tolerate only a few tenths of a percent DMSO before viability and transcription are affected — which sets a ceiling on the concentration–response curve independently of what the ligand does. And in an animal protocol the vehicle becomes a formulation problem in its own right, usually a DMSO, PEG or cyclodextrin system that has to be matched across arms.

A dropper bottle adds one more variable. Solvent evaporates from a bottle opened repeatedly, and the compound does not, so the concentration of a 20 mg/mL solution rises over the life of the bottle. Lyophilized peptide vials do not have this problem because the solid is weighed before the diluent is added. Keeping the closure tight and refrigerated, as these specifications ask, is partly a stability measure and partly a concentration-integrity one.

Degradation runs by different chemistry

Peptide failure modes are backbone and side-chain chemistry: hydrolysis of the amide bond, deamidation at asparagine and glutamine, methionine oxidation to the sulfoxide, disulfide scrambling where cysteines are present, and aggregation. They are driven by water, pH and dissolved oxygen, which is why lyophilized powder at −20 °C is stable for years and the same material in solution at 2–8 °C has a working life measured in weeks. The reasoning is set out in the peptide stability guide.

Small-molecule failure modes are substituent chemistry. YK-11's C-17 malonate ester is hydrolysable, which is the one genuinely labile bond in the AR series and a reason its liquid format wants refrigeration rather than ambient storage. Photodegradation matters across the class, which is why these ship in sealed bottles with desiccant and amber dropper bottles. But there is no backbone to hydrolyse and no side chain to deamidate, so a solid SARM sealed dry at room temperature is a more forgiving article than a lyophilized peptide — and correspondingly, in-vivo clearance is hepatic and oxidative rather than proteolytic, which changes what a metabolite study is looking for.

What a certificate can and cannot prove

For a peptide, reversed-phase HPLC purity plus electrospray mass spectrometry is a strong pair: the mass of a defined sequence is a tight constraint, and MS/MS fragmentation can confirm the sequence itself. The catalogue's peptides report ≥ 98% or ≥ 99% by HPLC with a lot-matched certificate, and how to read those sections is covered in the certificate-of-analysis guide.

For a small molecule the same two methods are weaker than they look. HPLC with UV detection establishes that one chromatographic species dominates. Mass spectrometry establishes a molecular formula. Neither distinguishes positional isomers or regiochemical variants that share a formula and co-elute, and in a heavily substituted aromatic scaffold those are exactly the plausible synthesis by-products. The method that resolves them is nuclear magnetic resonance: a proton NMR spectrum confirms substitution pattern in a way a mass cannot. When a SARM certificate reports HPLC and MS only, the right question is whether an NMR identity spectrum exists for that lot, and the general principle is the one in the mass spectrometry guide — ask what the method can actually exclude.

The compounds that sit in neither class

The clearest demonstration that target and chemistry are independent is ibutamoren. MK-677 is a non-peptide spiropiperidine of 528.66 g/mol that acts at growth hormone secretagogue receptor 1a — the same receptor as ipamorelin, GHRP-2, GHRP-6 and hexarelin. It is orally active with a reported half-life of around 24 hours in published pharmacokinetic work, where the hexapeptides are not orally viable at all. Same receptor, same pharmacological class, entirely different chemistry; and it is filed with the GHRPs and secretagogues rather than with the research compounds, because the target is what makes it belong there.

The rest of the small-molecule shelf is a mixture of unrelated mechanisms that the word "SARM" is often made to cover. SR9011 and SR9009 are Rev-Erb agonists acting at NR1D1 and NR1D2 to enhance transcriptional repression of BMAL1 — circadian and metabolic probes, not androgen ligands, and prohibited under WADA's metabolic-modulator category rather than its anabolic one. Cardarine is a PPAR-delta agonist. SLU-PP-332 is a pan-ERR agonist. BAM15 is a mitochondria-selective protonophore that uncouples respiration from ATP synthesis, with no receptor at all. Bromantane is an adamantane derivative described in the literature as an actoprotector, and phenylpiracetam is a racetam, piracetam with a phenyl group on the pyrrolidone ring, supplied as the racemate. Grouping these together describes a shelf, not a mechanism.

Documented status

Status is part of the definition for the androgen-receptor ligands, and the catalogue states it on each listing. No SARM is approved by the FDA or EMA for any indication. They are not lawful dietary ingredients in the United States, the FDA has issued public warnings against consumer use, and they are prohibited at all times under WADA's anabolic agents category, S1.2. US legislative proposals to schedule them have been introduced repeatedly.

Many research peptides are likewise unapproved, but the picture is less uniform: several peptide molecules in this catalogue exist as approved medicines in a different pharmaceutical article — tesamorelin, semaglutide and tirzepatide among them — and that approval attaches to the regulated article, not to research-grade powder of the same sequence. The distinction matters enough that it has its own glossary entry on FDA-approved versus research-grade material. Research peptides are also not steroids and not androgen ligands; the overlap people assume between the two shelves is mostly an artefact of where they are sold rather than of what they do.

Choosing for a study

If the research question is about androgen-receptor pharmacology — binding affinity, transactivation, coregulator recruitment, tissue-selectivity hypotheses, or anti-doping analytical method development, which several of these compounds are explicitly studied for — then an AR ligand is the only class that addresses it, and no peptide substitutes. If the question is about secretagogue or incretin signalling, matrix and repair biology, mitochondrial peptides or neurotrophic signalling, the peptides are the reagents and the AR ligands are irrelevant to it.

Where the two shelves genuinely meet is in muscle and bone tissue models, and even there they enter through different doors: the AR ligands as direct nuclear-receptor agonists, the peptides through the GH and IGF-1 axis or through myostatin and activin signalling. A design comparing them has to account for the mechanistic gap and for the vehicle mismatch, since one arm needs DMSO and the other does not. The catalogue's muscle-growth research overview sets out which molecules sit on which pathway. Nothing on this page describes human use, and no quantity, protocol or combination is recommended.